Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people globally suffer from celiac disease, for which ...
The trial's primary outcome measure is the Subjective Units of Distress Scale, a self-rated assessment by patients.
Zacks Small Cap Research on MSN8h
V.MDCX: Medicus Pharma Randomizes First Patient in SKNJCT-003 Phase 2 clinical trial for the treatment of nodular BCC (Basal Cell Carcinoma).MDCX READ THE FULL V.MDCX RESEARCH REPORT First Patient Randomized for Medicus Pharma’s Phase 2 Clinical Study (SKNJCT-003) ...
University of California San Diego is conducting new, Phase 2/3 national epilepsy clinical research trials, called Rise, to ...
Zacks Small Cap Research on MSN13h
EPIX: Masofaniten Combination Therapy with Enzalutamide Increases rPFS; Increasing Valuation to $33 per Share…EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Masofaniten plus Enzalutamide Results in Increased rPFS On September ...
(OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose ...
The European Commission (EC) has granted marketing authorisation to Leo Pharma ’s Anzupgo (delgocitinib) cream for treating ...
Biotech startup Ahammune Biosciences has raised $5 Mn (about INR 41 Cr) in its Series A round led by pi Ventures.
The trial is expected to commence in 2025 and is projected to last approximately two to three years. Immunological responses to the vaccine will be made available as the trial advances, providing a ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback